Cancer Research SABCS  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fulci, G.
Right arrow Articles by Van Meir, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fulci, G.
Right arrow Articles by Van Meir, E. G.
[Cancer Research 62, 2897-2905, May 15, 2002]
© 2002 American Association for Cancer Research


Molecular Biology and Genetics

Initiation of Human Astrocytoma by Clonal Evolution of Cells with Progressive Loss of p53 Functions in a Patient with a 283H TP53 Germ-line Mutation

Evidence for a Precursor Lesion1

Giulia Fulci2, Nobuaki Ishii, Daniela Maurici, Kim M. Gernert, Pierre Hainaut, Balveen Kaur and Erwin G. Van Meir3

Laboratory of Molecular Neuro-Oncology, Department of Neurosurgery, Hematology/Oncology and Winship Cancer Institute [G. F., B. K., E. G. V. M.] and BIMCORE [K. M. G.], Emory University School of Medicine, Atlanta, Georgia 30322; Laboratory of Tumor Biology and Genetics, 1011 Lausanne, Switzerland [G. F., N. I., E. G. V. M.]; and Mechanisms of the Carcinogenesis Unit, IARC, 69372 Lyon, cedex 08, France [D. M., P. H.]

Little is known about the genetic and molecular events leading to the early stages of humanastrocytoma formation. To examine this issue, we analyzed the significance of sequential accumulation of two somatic point mutations (R267W and E258D) in the TP53 gene during the initiation of astrocytoma in a patient born with a single germ-line p53 point mutation (R283H). We adapted a p53 transcriptional assay in yeast to establish the temporal occurrence and allelic distribution of the p53 mutations present in the patient and characterized these mutations through functional assays and structural modeling.

Our results show that the first somatic mutation occurred at codon 267 on the p53 allele harboring the germ-line mutation R283H, whereas the second somatic mutation occurred in the remaining wild-type (wt) allele at codon 258. These two mutations induced the formation of tumor cells with the genotype p53267W+283H/258D, which comprised 70% of the cells in the primary WHO grade II astrocytoma. Another 8% of cells within the tumor had the partially mutated genotype p53267W+283H/WT and represented the remnants of a clinically undetectable intermediate stage of astrocytic neoplastic transformation. The remaining 22% of cells had the constitutive p53283H/WT genotype and likely consisted of nontumor cells. Functional analysis of the p53 alleles present in the patient’s tumor indicated that the germ-line p53R283H could transactivate the CDKN1A(p21, WAF1, cip1, SDI1) but not the BAX gene and retained the ability to induce growth arrest of human glioblastoma cells. The p53R267W+R283H and p53E258D were incapable of transactivating either promoter or inducing growth arrest. Modeling of p53 interaction with DNA suggests that R283H mutation may weaken the sequence-specific interaction of p53 lysine 120 with the BAX gene but not the CDKN1A p53-responsive elements.

Taken together, these results have characterized, for the first time, the genetic events defining a clinically undetectable precursor lesion leading to a grade II astrocytoma. They also suggest that astrocytoma initiation in this patient resulted from monoclonal evolution driven by a sequential loss of proapoptotic and growth arrest functions of p53.




This article has been cited by other articles:


Home page
Cold Spring Harb Symp Quant BiolHome page
J.N. Rich and C.E. Eyler
Cancer Stem Cells in Brain Tumor Biology
Cold Spring Harb Symp Quant Biol, March 27, 2009; (2009) sqb.2008.73.060v1.
[Abstract] [PDF]


Home page
J. Mol. Diagn.Home page
J. M. Sayagues, M. D. Tabernero, A. Maillo, A. Espinosa, A. Rasillo, P. Diaz, J. Ciudad, A. Lopez, M. Merino, J. M. Goncalves, et al.
Intratumoral Patterns of Clonal Evolution in Meningiomas as Defined by Multicolor Interphase Fluorescence in Situ Hybridization (FISH): Is There a Relationship between Histopathologically Benign and Atypical/Anaplastic Lesions?
J. Mol. Diagn., November 1, 2004; 6(4): 316 - 325.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Fouquet, M. Antoine, P. Tisserand, R. Favis, M. Wislez, F. Commo, N. Rabbe, M. F. Carette, B. Milleron, F. Barany, et al.
Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array: A Prospective Study
Clin. Cancer Res., May 15, 2004; 10(10): 3479 - 3489.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.